|
Feb 28
|
Pharming Group to participate in March investor conference
|
|
Feb 27
|
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
|
|
Feb 20
|
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
|
|
Feb 11
|
High Growth Tech And These 3 Dynamic Stocks with Promising Expansion
|
|
Oct 10
|
Pharming Group to report third quarter 2024 financial results on October 24
|
|
Apr 4
|
Pharming Group announces the 2024 Annual General Meeting of Shareholders
|
|
Apr 4
|
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
|
|
Apr 3
|
Pharming Group to participate in April investor conferences
|
|
Feb 29
|
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
|
|
Aug 9
|
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan
|